96089-74-6

Upstream product

• 90-98-2 4,4'-Dichlorobenzophenone 
• 1102376-68-0 2,2-bis(4-chlorophenyl)oxetane 
• 95269-22-0 ethyl 3,3-bis(4'-chlorophenyl)prop-2-enoate 

Downstream Products

• 462093-66-9 4,4'-(3-chloroprop-1-ene-1,1-diyl)bis(chlorobenzene) 
• 1265080-38-3 C₂₃H₂₂Cl₂O 
• 1265081-19-3 C₂₉H₂₆Cl₂O 

Relevant academic research and scientific papers

Characterization of Highly Coordinated Allylgermanes: Pivotal Players for Enhanced Nucleophilicity and Stereoselectivity

Allylgermanes with a 4-, 5-, and 6-coordinated germanium center were characterized by X-ray crystallography. Cationic 6-coordinated group 14 allylmetals, which were hitherto assumed to be a transition-state structure of allylations, were successfully isol

Titanocene catalyzed opening of oxetanes

The reductive opening of oxetanes by Cp2TiCl was investigated by a combined synthetic and computational study. The activation and reaction energies predict a more difficult reaction than the related epoxide opening. Synthetically, the γ-titanoxy radicals obtained behave like typical free radicals. Their reactions are not controlled by the metal and its ligands. This is highlighted by the dimerization of phenyl substituted oxetane derived radicals.

Novel compounds, their preparation and use

Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be u

NOVEL COMPOUNDS, THEIR PREPARATION AND USE

Novel compounds of the general formula (I), the use of these compounds as pharma-ceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be

Synthesis of novel diazatricyclodecanes (DTDs). Effects of structural variation at the C3′ allyl end and at the phenyl ring of the cinnamyl chain on μ-receptor affinity and opioid antinociception

Two series of analogues of 9-propionyl-10-cinnamyl-9,10-diazatricyclo[4.2.1.12,5]decane (1a) and 2-propionyl-7-cinnamyl-2,7-diazatricyclo[4.4.0.03,8]decane (2a), in which the cinnamyl moiety was replaced by various aralkenyl chains,

N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-opioid receptor agonists. Effects on μ-affinity of arylalkenyl chain modifications

Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid μ-, δ- and κ-receptors were evaluated. Several compounds (1e,i,j-2d,e,f,g,j) exhibited a μ-affinity in the low nanomolar range with moderate or negligible affinity towards δ- and κ-receptors. The representative term N-9-(3,3-diphenylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine.

Arylalkylaminobenzoic acids

This disclosure describes novel [Bis(phenyl or substituted phenyl)alkyl]amino benzoic acids, esters, and derivatives thereof. These compounds are useful pharmaceutical agents for ameliorating atherosclerosis by inhibiting the formation and development of atherosclerotic lesions in the arterial walls of mammals.